Teva Pharmaceutical Industries Ltd. announced on Monday that the U.S. District Court for the District of New Jersey has issued a favorable ruling in the Company’s patent infringement lawsuit against Mylan regarding an Azilect (rasagiline tablets) patent which covers methods of treating Parkinson’s disease. The Court has upheld the validity of Teva’s patent.
Teva’s patent expires in 2017, and they are hopeful that this development will result in an injunction against Mylan launching a generic equivalent before then.
Teva said it filed a lawsuit suit against Mylan in October 2010. Similar lawsuits were filed against Watson and Orchid in October 2010, Apotex in May 2011 and Sandoz in April 2012. Teva reached settlement agreements with Watson, Apotex and Orchid earlier this year. Sandoz has agreed to be bound by a final judgment in the case against Mylan.